Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials-Reference-Cited by-全球学者库

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Published:2015-02 Issue:2 Volume:16 Page:141-151
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Yang James Chih-Hsin,Wu Yi-Long,Schuler Martin,Sebastian Martin,Popat Sanjay,Yamamoto Nobuyuki,Zhou Caicun,Hu Cheng-Ping,O'Byrne Kenneth,Feng Jifeng,Lu Shun,Huang Yunchao,Geater Sarayut L,Lee Kye Young,Tsai Chun-Ming,Gorbunova Vera,Hirsh Vera,Bennouna Jaafar,Orlov Sergey,Mok Tony,Boyer Michael,Su Wu-Chou,Lee Ki Hyeong,Kato Terufumi,Massey Dan,Shahidi Mehdi,Zazulina Victoria,Sequist Lecia V

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Treating patients with EGFR-sensitizing mutations: first line or second line-is there a difference?;Mok;J Clin Oncol,2013

2. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 1341 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: A lung squamous cell carcinoma patient with a rare EGFR G719X mutation and high PD-L1 expression showed a good response to anti-PD1 therapy;Frontiers in Oncology;2024-01-31

2. Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study;BMC Cancer;2024-01-12

3. Integrated Analyses of Multi-omic Data Derived from Paired Primary Lung Cancer and Brain Metastasis Reveals the Metabolic Vulnerability as a Novel Therapeutic Target;2024-01-02

4. Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis;Translational Oncology;2024-01

5. Compromised Outcomes in Stage IV Non–Small-Cell Lung Cancer With Actionable Mutations Initially Treated Without Tyrosine Kinase Inhibitors: A Retrospective Analysis of Real-World Data;JCO Oncology Practice;2024-01